The latter is further supported with the findings that glibenclamide, a widely used KATP channel inhibitor is an agonist of TRPA1 [59], and it has been suggested that the synergistic effect of TRPA1 and KATP channels underlies the hyperinsulinism in patients with glibenclamide treatment. The gene discussed is TRPA1; the disease is hyperinsulinism.